

From: Do, Yu
Sent: Thursday, September 17, 2015 9:11 AM
To: Erik.Bjornson@baxalta.com
Subject: Information Request: PMR/PMC Protocols (Response Due by TODAY, September 17, 2015) - Original BLA 125566/0, Anti hemophilic Factor (Recombinant), PEGylated [ADYNOVATE]
Attachments: Adynovate PMC PMR Proposal __cber-fs3_m_ectd_submissions_bla125566_0036_m1_us_multiple-module-info-amend-pmc-pmr-us.pdf

Dear Mr. Bjornson:

We are reviewing your original November 25, 2014 submission to BLA 125566/0 for Anti hemophilic Factor (Recombinant), PEGylated. We determined that the following information is necessary to continue our review:

1. Please provide the submission dates and serial numbers for all versions of the following PMR/PMC protocols for which the last submission was on July 22, 2015:

Protocol 261202, Protocol 261204, and Protocol 261302

Attached is a relevant document for your reference, which was included in the Amendment submitted on August 28, 2015.

The review of this submission is ongoing and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file by September 17, 2015, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is November 25, 2015.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or Yu.Do@fda.hhs.gov if you have any questions.

Sincerely,

Yu Do, M.S.
Regulatory Project Manager
FDA/OMPT/CBER/OBRR/IOD/RPMS
(240) 402-8343
yu.do@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."

1.11.4 Multiple Module Information Amendment

1. NATURE AND PURPOSE OF THE AMENDMENT

Baxalta US Inc is providing a proposed list of Post-marketing Requirement (PMR) and Post-marketing Commitment (PMC) studies as requested by the Agency in the 05 AUG 2015 and 27 AUG 2015 teleconferences between Baxalta and the FDA.

As noted in the 27 AUG 2015 teleconference, with the exception of the clinical study being performed in previously untreated patients (clinical study 261203), the pediatric component of clinical studies described in the agreed upon Pediatric Study Plan for BAX 855 will be considered Post-marketing Requirement studies, refer to 1.9.4 [Request for Deferral of Pediatric Studies and Proposed Pediatric Study Plan Amended](#) (STN: BL 125566 sequence 0000). Such studies will also be noted as Post-marketing Commitment studies.

2. POSTMARKETING REQUIREMENT STUDIES

Baxalta is proposing the following post-marketing requirement studies for ADYNOVATE:

1. A Phase 3 prospective, uncontrolled, and multi-center study to evaluate PK, efficacy, safety, and immunogenicity of ADYNOVATE in pediatric previously treated patients (PTPs) less than 12 years of age (clinical study 261202)

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	22 July 2015
Study Completion:	15 November 2015
Final Report Submission:	30 June 2016

2. A Phase 3, prospective, open label multi-center study of efficacy and safety of ADYNOVATE in the perioperative management of bleeding in PTPs age 2-75 years (clinical study 261204) – **PEDIATRIC COMPONENT ONLY**

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	22 July 2015
Study Completion:	31 March 2017
Final Report Submission:	31 December 2017

3. A Phase 3b, prospective, open label, and multi-center continuation study of safety and efficacy of ADYNOVATE in the routine prophylaxis of bleeding to reduce the frequency of bleeding episodes in PTPs (clinical study 261302) - **PEDIATRIC COMPONENT ONLY**

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	22 July 2015
Study Completion:	31 December 2017
Final Report Submission:	30 September 2018

4. A Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A (clinical study 261303) - **PEDIATRIC COMPONENT ONLY**

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	31 December 2015
Study Completion:	31 December 2018
Final Report Submission:	30 September 2019

3. POSTMARKETING COMMITMENT STUDIES

Baxalta is proposing the following post-marketing commitment studies for ADYNOVATE:

1. A Phase 3, prospective, open label multi-center study of efficacy and safety of ADYNOVATE in the perioperative management of bleeding in PTPs age 2-75 years (clinical study 261204)

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	22 July 2015
Study Completion:	31 March 2017
Final Report Submission:	31 December 2017

2. A Phase 3b, prospective, open label, and multi-center continuation study of safety and efficacy of ADYNOVATE in the routine prophylaxis of bleeding to reduce the frequency of bleeding episodes in PTPs (clinical study 261302)

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	22 July 2015
Study Completion:	31 December 2017
Final Report Submission:	30 September 2018

3. A Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A (clinical study 261303)

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	31 December 2015
Study Completion:	31 December 2018
Final Report Submission:	30 September 2019

4. A Phase 3, multi-center, open label study to investigate safety and immunogenicity of ADYNOVATE in previously untreated patients (PUPs) (clinical study 261203)

We propose to conduct this clinical trial according to the following schedule:

Final protocol submission:	15 June 2015
Study Completion:	31 December 2022
Final Report Submission:	30 September 2023